Aurora Cannabis Inc.
NASDAQ:ACBDrug Manufacturers - Specialty & Generic
+$0.02 today
- Market cap
- $289.28M
- Beta
- 1.34
- P/E (TTM)
- -3.2
- EPS (TTM)
- -$1.31
Volume 0.92M
Average 1.00M
ACB Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Aurora Cannabis Inc.NASDAQ: ACB
Capital Expenditures · Q4 FY2026 · quarter ended Mar 2026
Capital expenditures grows in line with its trailing trend
Q4 FY2026 capital expenditures of CA$5.19M (cash outflow) rose 20.5% year over year, ahead of the +19.6% change in trailing-twelve-month capital expenditures. Sequentially, it fell 13.2% from the prior quarter. Over 3 fiscal years it compounded at +23.0% a year.
Context
- Capital expenditures amounted to 7.0% of revenue in FY2026, up 1.5 pp from a year earlier.
- Capital expenditures grew in size in 3 of the last 3 fiscal years.
- FY2026 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +20.5% holds above the trailing-twelve-month pace of +19.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
CAD · from the cash flow
- Latest · FY2026
- (22.6M) CAD
- Year-over-year change
- -19.9%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | (22.6M) | -19.9% |
| FY2025 | 2025-03-31 | (18.86M) | -12.0% |
| FY2024 | 2024-03-31 | (16.83M) | -38.8% |
| FY2023 | 2023-03-31 | (12.13M) | +62.3% |
| FY2022 | 2022-06-30 | (32.21M) | — |
Capital Expenditures vs competitors
How ACB compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +19.6% is the 2nd highest of 10, against a peer median of -41.0%.
- Capital expenditures amounts to 7.3% of revenue for ACB, versus a peer median of 2.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$22.56M CAD | +19.6% | +23.0% | 7.3% | |
| LTM Mar 2026 | CA$11.4M CAD | +2.4% | — | 4.2% | |
| LTM Apr 2026 | CA$10.14M CAD | -5.9% | +5.5% | 1.5% | |
| LTM Mar 2026 | $9.17M USD | +175.1% | -9.6% | 4.2% | |
| LTM Mar 2026 | $6.91M USD | — | -23.5% | 5.1% | |
| LTM Mar 2026 | CA$6.66M CAD | -41.0% | -10.7% | 2.1% | |
| LTM Mar 2026 | $1.16M USD | -4.6% | -65.6% | 2.8% | |
| LTM Mar 2026 | $585K USD | -91.7% | -47.2% | 1.5% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $319K USD | -59.7% | +91.1% | 3.1% |
| LTM Mar 2026 | $81K USD | -99.8% | -43.2% | 1.0% | |
| LTM Mar 2026 | $3K USD | -97.1% | -37.0% | 0.0% | |
| Peer median (excluding ACB) | — | -41.0% | -23.5% | 2.5% | |
Competitors are the stored peer set for ACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Jun 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Net Income | (1.72B) | (265.33M) | (57.08M) | 15.76M | (58.77M) |
| Depreciation & Amortization | 93.66M | 43.57M | 32.78M | 22.55M | 14.23M |
| Deferred Income Tax | (2.19M) | (18.4M) | (1.67M) | (3.19M) | 55.14K |
| Stock-Based Compensation | 13.76M | 16.89M | 12.72M | 11.52M | 7.29M |
| Change in Working Capital | 52.65M | (25.12M) | (15.54M) | 10.21M | (9.24M) |
| Accounts Receivables | 18.34M | 5.53M | (4.5M) | 5.24M | (8.17M) |
| Inventory | 21.07M | 49.03M | 3.87M | (15.05M) | 65.93M |
| Accounts Payables | 6.77M | (8.06M) | (15.7M) | 14.91M | (8.06M) |
| Other Working Capital | 6.48M | (71.61M) | 790K | 5.11M | (58.93M) |
| Other Non-Cash Items | 1.45B | 190.11M | (39.71M) | (40.85M) | 40.18M |
| Operating Cash Flow | (110.27M) | (115.82M) | (68.51M) | 16.01M | (13.55M) |
| Capital Expenditures | (32.21M) | (12.13M) | (16.83M) | (18.86M) | (22.6M) |
| Acquisitions (Net) | (23.42M) | (18.54M) | (5.55M) | 0 | 1.1M |
| Purchases of Investments | 0 | 0 | 0 | 0 | (52.35M) |
| Sales of Investments | 0 | 3.36M | 4.99M | 5.49M | 0 |
| Other Investing Activities | 19.46M | 16K | 14.02M | (956K) | 235.61K |
| Investing Cash Flow | (36.17M) | (27.29M) | (3.36M) | (14.33M) | (73.62M) |
| Debt Repayment | (170.83M) | — | (85.37M) | (805K) | (5.02M) |
| Common Stock Issued | 350.19M | 73.19M | 37.92M | 820K | 9.94M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (31.58M) | (95.21M) | (475K) | (131K) | (154.4K) |
| Financing Cash Flow | 147.78M | (56.48M) | (47.92M) | (116K) | 9.79M |
| Effect of Forex Changes | 15.01M | 15.54M | 297K | 264K | 10.56M |
| Net Change in Cash | 16.35M | (140.01M) | (119.5M) | 1.83M | (66.81M) |
| Free Cash Flow | (142.48M) | (127.95M) | (85.34M) | (2.85M) | (36.15M) |
Aurora Cannabis Inc.
NASDAQ:ACB
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.